Key Details
Price
$8.81Annual ROE
-309.46%Beta
0.93Events Calendar
Next earnings date:
Mar 28, 2025Recent quarterly earnings:
Nov 13, 2024Recent annual earnings:
Mar 29, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Jun 2, 2023Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
We have put together a list of the 15 healthcare stocks that are performing exceptionally well in 2025. In this article, we will examine how Elicio Therapeutics Inc (NASDAQ:ELTX) compares to other healthcare stocks. The healthcare industry is recovering in 2025 after two years of poor performance.
Interim analysis from the phase 1/2 AMPLIFY-7P study, using ELI-002 for the treatment of KRAS mutant pancreatic cancer patients, is expected in the 1st half of 2025. The global pancreatic cancer market size is expected to reach $7.4 billion by 2032; It is said that approximately 88% of PDAC cases deal with the KRAS mutation. The company has already established a proposed phase 3 design with the FDA in a Type B meeting using ELI-002 for the treatment of patients with KRAS-mutant pancreatic cancer.
Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, patient population and primary endpoint analysis
BOSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on October 15, 2024, Elicio granted an aggregate of 5,900 inducement stock options to two new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio's Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan.
BOSTON, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on September 16, 2024, Elicio granted an aggregate of 4,800 inducement stock options to a new employee, as an inducement material to the individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio's Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan.
BOSTON, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced upcoming presentations in September and October.
• AMPLIFY-7P Phase 1 preliminary disease-free (“DFS”) survival demonstrates strong correlation between T cell response and reduced risk of progression or death• AMPLIFY-7P Phase 1 data presented at ASCO demonstrated 100% of patients develop mKRAS-specific T-cell response with ~66% of responses including both CD4+ and CD8+ T cells• Long term follow up of the AMPLIFY-201 Phase 1 study will be terminated, and long term follow up of the AMPLIFY-7P Phase 1 study will be minimized to collect only overall survival to preserve resources with updated data to be shared at upcoming medical meetings• AMPLIFY-7P Phase 2 randomized clinical trial anticipated to complete 135-patient enrollment in the fourth quarter of 2024• $43 million raised in 2024 funds Elicio into the second quarter of 2025
Elicio Therapeutics (NASDAQ: ELTX ) stock is falling on Friday after the clinical-stage biotechnology company announced a proposed public offering. Elicio Therapeutics has announced its plans for a public offering that will include shares of ELTX stock, warrants to purchase additional shares and pre-funded warrants.
BOSTON, June 27, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has commenced an underwritten public offering of its shares of common stock and accompanying common warrants and, in lieu of its shares of common stock to certain investors that so choose, pre-funded warrants to purchase shares of common stock and accompanying common warrants. All of the common stock, pre-funded warrants and accompanying common warrants are being offered by Elicio. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
ELI-002 7P administered as a monotherapy at the Phase 2 dose shows preliminary encouraging Disease-Free Survival data in pancreatic ductal adenocarcinoma ELI-002 7P administered as a monotherapy at the Phase 2 dose shows preliminary encouraging Disease-Free Survival data in pancreatic ductal adenocarcinoma
FAQ
- What is the ticker symbol for Elicio Therapeutics?
- Does Elicio Therapeutics pay dividends?
- What sector is Elicio Therapeutics in?
- What industry is Elicio Therapeutics in?
- What country is Elicio Therapeutics based in?
- When did Elicio Therapeutics go public?
- Is Elicio Therapeutics in the S&P 500?
- Is Elicio Therapeutics in the NASDAQ 100?
- Is Elicio Therapeutics in the Dow Jones?
- When was Elicio Therapeutics's last earnings report?
- When does Elicio Therapeutics report earnings?
- Should I buy Elicio Therapeutics stock now?